publication venue for
- Promising response of dabrafenib, trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations. 35:109-115. 2024
- Influence of statistician involvement on reporting of randomized clinical trials in medical oncology. 24:306-309. 2013
- Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells. 20:115-122. 2009
- Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors. 17:81-87. 2006
- Doxycycline and other tetracyclines in the treatment of bone metastasis. 14:773-778. 2003
- Selective cytotoxicity of gemcitabine in bladder cancer cell lines. 13:557-566. 2002
- Pattern of carboplatin-induced emesis. 6:645-651. 1995
- Oligonucleotide degradation contributes to resistance to antisense compounds. 4:197-200. 1993